Summary:
Miami Dade Medical Research Institute is conducting a 26 week study to evaluate the efficacy, safety, and tolerability of an investigational product in the treatment of subjects with type 2 diabetes mellitus with inadequate glycemic control on metformin and on sitagliptin therapy.
Qualified Participants Must:
• Have Type 2 Diabetes Mellitus
•
Be between 18 and 75 Years of age
•
Have an HbA1c between 7.5% and 10.5%
•
Be being treated with metformin and sitagliptin at a stable dose for at least 12 weeks before screening
.
Qualified Participants May Receive:
Stipend for time and travel.